Inactive Instrument

Other languages Freeline Therapeutics Holdings plc

Equities

FRLN

US35655L2060

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Late-Breaking Oral Presentation at ASGCT 27th Annual Meeting	May. 09
Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting	Apr. 24
Syncona’s Takeover of Freeline Therapeutics Becomes Effective	Feb. 20
Freeline Therapeutics Holdings plc Announces Resignation of Julia Gregory, Martin Andrews, Jeffrey Chodakewitz, Colin Love and Paul Schneider from the Board	Feb. 20
Acquisition of Freeline by Syncona Becomes Effective	Feb. 20
Freeline Therapeutics Holdings plc(NasdaqCM:FRLN) dropped from NASDAQ Composite Index	Feb. 19
Syncona Investment Management Limited completed the acquisition of the remaining 42.08% stake in Freeline Therapeutics Holdings plc.	Feb. 19
Freeline shareholders approve Syncona acquisition	Feb. 12
Freeline Therapeutics' Shareholders Approve Acquisition by Syncona	Feb. 12
Freeline Shareholders Approve Acquisition by Syncona	Feb. 12
Syncona says Freeline trial for Gaucher disease treatment positive	Jan. 19
European Equities Traded in the US as American Depositary Receipts Gain Friday	Dec. 22
Hemophilia Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 \| Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics	Dec. 08
Freeline Therapeutics : Reports Second Quarter 2023 Financial Results and Business Highlights - Form 6-K	Dec. 01
Freeline Therapeutics Holdings plc Reports Earnings Results for the Nine Months Ended September 30, 2023	Dec. 01
FREELINE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Freeline Therapeutics Holdings plc - FRLN	Nov. 28
HC Wainwright Downgrades Freeline Therapeutics to Neutral From Buy, Adjusts Price Target to $6.50 From $15	Nov. 28
Sector Update: Health Care Stocks Advance Late Afternoon	Nov. 22
Sector Update: Health Care Stocks Higher in Afternoon Trading	Nov. 22
FTSE 100 Closes Down 0.17% After Autumn Statement	Nov. 22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Freeline Therapeutics Holdings plc

Equities

FRLN

US35655L2060

Other languages

Filters